MoonLake Immunotherapeutics
MLTXMoonLake Immunotherapeutics is a clinical-stage biotechnology company dedicated to developing novel therapies for inflammatory skin and joint diseases.
Earnings
Next report
Aug 11, 2026 (In 2 days)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company dedicated to developing novel therapies for inflammatory skin and joint diseases. The company's core value proposition centers on its proprietary Nanobody technology, which offers enhanced tissue penetration and manufacturing advantages over traditional monoclonal antibodies. Its primary focus is the clinical advancement of sonelokimab (SLK), a tri-specific inhibitor targeting IL-17A and IL-17F to address significant unmet needs in dermatology and rheumatology.
A clinical-stage innovator utilizing a specialized Nanobody platform to differentiate from established monoclonal antibody treatments in the IL-17 inhibitor market.
FAQ
- What is MoonLake Immunotherapeutics's market cap?
- MoonLake Immunotherapeutics (MLTX) has a market capitalization of $1.5B and trades on NASDAQ.
- Who are MoonLake Immunotherapeutics's competitors?
- MoonLake Immunotherapeutics's key competitors include Eli Lilly and Company, Shattuck Labs, Inc. Common Stock, Kymera Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does MoonLake Immunotherapeutics partner with?
- MoonLake Immunotherapeutics's notable partners include Merck KGaA, Avillion LLP, Sanofi.
- Where is MoonLake Immunotherapeutics headquartered?
- MoonLake Immunotherapeutics is headquartered in Switzerland and employs approximately 50 people. It has been publicly traded since 2022.